Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Studies in target-based treatment.

Razelle Kurzrock1

  • 1Phase I Program, Division of Cancer Medicine, Unit 422, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009, USA. rkurzroc@mdanderson.org

Molecular Cancer Therapeutics
|May 8, 2007
PubMed
Summary

Molecular cancer therapeutics are revolutionizing treatment by targeting specific cancer cell mechanisms. Early clinical responses show promise for conditions like chronic myelogenous leukemia and Li Fraumeni Syndrome.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match.

The oncologist·2018
Same author

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2018
Same author

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial.

JAMA oncology·2018
Same author

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2018
Same author

Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing.

Cancer biology & therapy·2018
Same author

Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).

Cancer biology & therapy·2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Therapeutics

Background:

  • Targeted molecular therapies offer a new paradigm in cancer treatment by selectively targeting cancer cells.
  • Agents like imatinib mesylate demonstrate remarkable efficacy and minimal toxicity in specific cancers.

Purpose of the Study:

  • To highlight the rapid publication of groundbreaking discoveries in target- or mechanism-based clinical responses in cancer.
  • To showcase the potential of molecular cancer therapeutics in altering the clinical treatment landscape.

Main Methods:

  • Review of emerging clinical data on targeted cancer therapies.
  • Case study of adenoviral p53 therapy for Li Fraumeni Syndrome.

Main Results:

  • Imatinib mesylate shows over 90% response rates in early-stage chronic myelogenous leukemia.
  • Gastrointestinal stromal tumors (GIST) exhibit rapid metabolic responses to imatinib.
  • Successful adenoviral p53 gene therapy demonstrated in a Li Fraumeni Syndrome patient.

Conclusions:

  • The era of molecular cancer therapeutics has commenced, offering new hope for patients.
  • Early clinical successes, such as p53 gene therapy, warrant further investigation in sporadic cancers.
  • Rapid dissemination of clinical findings is crucial for advancing cancer research and patient benefit.

Related Experiment Videos